Dr. Tim Corson earned his B.S.c., M.S.c.m, and Ph.D. degrees from the University of Toronto, Canada. While at the University of Toronto, Corson’s dissertation work with advisor Dr. Brenda L. Gallie included the discovery of KIF14 as an oncogene in retinoblastoma and other cancers. Corson later completed chemical biology research as the Canadian Institutes of Health Research Jean-Francois St-Denis Fellow in Cancer Research at Yale University. Corson began his teaching career at Indiana University School of Medicine (IUSM) in 2010 as an assistant professor in the Department of Ophthalmology. He was promoted to associate professor in 2017 and full professor in 2022. He served as the Interim Director of Basic and Translational Research from 2017 to 2018 before serving as full director in 2018. He began serving as the vice chair for Basic and Translational Research upon completion of his directorship in 2022. Corson was also appointed as the Merrill Grayson Senior Chair in Ophthalmology in 2019. His research interests include the discovery and development of novel compounds and their targets for the treatment of ocular tumors and neovascular eye diseases like macular degeneration. His research has led to more than 80 papers and 10 patents and has been supported by grants from the National Eye Institute, Retina Research Foundation, BrightFocus Foundation, and other agencies. Other honors include the CTSI Watanabe Translational Scholar, ICBI Entrepreneur-in-Residence, and Showalter Scholar. Corson is a member of the Simon Comprehensive Cancer Center, the Stark Neurosciences Research Institute, and the Center for Diabetes and Metabolic Diseases.